WASHINGTON — It’s not every day that the pharmaceutical industry, the NAACP, a cancer center, and a nonpartisan think tank are all lobbying to achieve the same policy goal.
But an effort to expand Medicare coverage for obesity drugs has managed to unite them all, and many more groups across the health care industry, too.
Medicare is prohibited by law from paying for the buzzy new drugs that promise to help people with obesity lose weight. Lawmakers banned coverage of obesity drugs when the program’s prescription drug benefit was created in 2003, along with medications to treat conditions such as erectile dysfunction, hair loss, and fertility issues.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect